This combination tablet contains Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate, offering a powerful, single-tablet regimen for the treatment of human immunodeficiency virus (HIV) infection. This formulation is designed to enhance adherence and improve treatment outcomes for patients.

Key Features:

Triple-Action Formula:

Dolutegravir: An integrase inhibitor that blocks the integration of viral DNA into the host genome, effectively reducing viral load.
Lamivudine: A nucleoside reverse transcriptase inhibitor (NRTI) that interferes with the viral replication process.
Tenofovir Disoproxil Fumarate: Another NRTI that helps prevent the replication of HIV, further lowering the viral load.
Simplified Dosing: Administered as a single daily tablet, this combination therapy simplifies treatment and helps improve adherence to the regimen.

Proven Efficacy: Supported by extensive clinical trials, this combination has shown significant effectiveness in achieving viral suppression and maintaining immune function.

Well-Tolerated: Most patients tolerate this combination well, although regular monitoring for potential side effects is recommended.

Very secured payment methods

Shipping will be calculated on checkout

Please note that price may increase due to exchange rate, ensure updated price before making payment